BCL2L1 and neoplasm: BCL-XL provoked particular interest, as its transcripts were increased by 83% in FLC tumors compared with adjacent normal tissues, and some therapeutically resistant patient-derived xenografts (PDX) tumor lines showed significant upregulation (160%) compared with adjacent normal liver tissue.